Immunotherapy in Aml: A Brief Review on Emerging Strategies Publisher Pubmed



Moeinafshar A^{1, 2} ; Hemmati S^{1, 2} ; Rezaei N^{3, 4, 5} Show Affiliations
Source: Clinical and Translational Oncology Published:2021

Abstract

Acute myeloid leukemia (AML), the most common form of leukemia amongst adults, is one of the most important hematological malignancies. Epidemiological data show both high incidence rates and low survival rates, especially in secondary cases among adults. Although classic and novel chemotherapeutic approaches have extensively improved disease prognosis and survival, the need for more personalized and target-specific methods with less side effects have been inevitable. Therefore, immunotherapeutic methods are of importance. In the following review, primarily a brief understanding of the molecular basis of the disease has been represented. Second, prior to the introduction of immunotherapeutic approaches, the entangled relationship of AML and patient’s immune system has been discussed. At last, mechanistic and clinical evidence of each of the immunotherapy approaches have been covered. © 2021, Federacion de Sociedades Espanolas de Oncologia (FESEO).